Eli Lilly and Company (LLY)

Peter Marks, the former top vaccine regulator at the U.S. Food and Drug Administration, has joined Eli Lilly , STAT News reported on Tuesday.

Zacks.com users have recently been watching Lilly (LLY) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.

Why investors should use the Zacks Earnings ESP tool to help find stocks that are poised to top quarterly earnings estimates.

Approximately 80% of Omvoh-treated patients in the LUCENT-3 study who achieved clinical remission at one year maintained long-term, corticosteroid-free clinical and endoscopic remission At four years, nearly all patients who achieved clinical remission at one year had improvements in bowel urgency, one of the most disruptive symptoms for patients INDIANAPOLIS , Oct. 7, 2025 /PRNewswire/ -- New data from Eli Lilly and Company (NYSE: LLY) showed Omvoh (mirikizumab-mrkz) is the first and only interleukin-23p19 (IL-23p19) to help patients with moderately to severely active ulcerative colitis (UC) achieve sustained, long-term outcomes through four years. The results were seen across multiple symptomatic, clinical, endoscopic, histologic and quality-of-life measures, including among patients who had previously failed a biologic or advanced therapy (27%).

After tanking in early August, the world's most valuable pharmaceutical stock has roared back with a vengeance. That firm is Eli Lilly and Company NYSE: LLY, the maker of the wildly popular weight loss and diabetes drugs Zepbound and Mounjaro.

LLY shares have jumped 16% last week as Pfizer's landmark government deal boosted investor confidence across the pharma sector.

When investors hear that a company will lower prices on its products, their instinctive reaction is to expect a sequential decline in margins and profits, which is not entirely incorrect. However, sometimes these price decreases end up attracting new business, expanding market share, and more than making up for the lost ticket price in the top-line revenue.

While AI hype reigns on Wall Street, the healthcare sector is still far from the peaks it reached during the COVID-19 pandemic. And what's more important, many of the biotech stocks remain outside of Mr. Market's interest zone. Since the exclusivity of key blockbusters of 'giants', including Merck and Pfizer, expires in the next 4 years, there is an urgent need to continue rejuvenating their portfolios of drugs.

Eli Lilly (LLY 1.15%) is now known for its weight loss drugs. Its stock has risen 150% since mid-2022 because of high demand for Mounjaro (tirzepatide approved to treat type 2 diabetes) and Zepbound (tirzepatide approved for weight loss).

Eli Lilly will invest more than $1 billion in India in the coming years to boost manufacturing and supply through local drugmakers, the company said on Monday, as it seeks to tap into skilled workforce to bolster its global manufacturing expansion.

Eli Lilly (LLY) closed the most recent trading day at $839.87, moving +2.44% from the previous trading session.

Shares in Eli Lilly (LLY 2.73%) had risen 13.2% in the week to Friday morning. The move comes at a time when peer Pfizer announced a deal with the Trump administration that gave that pharmaceutical company three years of grace from tariffs imposed on drugs it manufactures abroad and imports to the U.S..

I track a universe of 50 high-quality dividend growth stocks to identify opportune investments based on valuation and future return potential. As of October 2, 2025, 22 stocks offer attractive future return estimates of at least 10%, with 15 appearing potentially undervalued by my Free Cash Flow model. Top-ranked stocks include MKTX, RMD, MPWR, RACE, and MSCI, each offering strong projected returns driven by yield, valuation upside, and EPS growth.

BOSTON--(BUSINESS WIRE)-- #AI--Kernal Bio retains strategic independence, while gaining access to shared resources, operational support and Lilly's global network of experts.

The entire pharmaceutical sector is experiencing a rerating this week, as investors realize the adverse impact of tariffs and drug price cuts won't be as severe as previously anticipated. While most major pharma stocks have rallied, Eli Lilly stock (NYSE: LLY) warrants particular attention.

Building a resilient retirement portfolio requires a mix of disruption-proof income from REITs, midstream energy, and high-yielding assets, plus growth stocks and ETFs. Current market challenges—AI disruption, weak job market, inflation risks—make long-term planning difficult, but also highlight the need for self-reliance and diversification. Core portfolio holdings should include large, proven REITs, natural gas midstream companies, select high-yield stocks, BDCs, preferred equity ETFs, and actively managed income funds.